ARTL

Business Context and Reporting Period

Company: Artelo Biosciences, Inc. (ARTL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system (ECS). Key programs include ART27.13 (cancer-related anorexia), ART26.12 (chemotherapy-induced peripheral neuropathy), and ART12.11 (CBD cocrystal). The company has incurred losses since inception and has not generated any revenue.

Key Financial Metrics

Note: All figures in thousands except per share data. Working capital is negative due to current liabilities exceeding current assets.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased significantly to $3.1 million in Q3 2025 from $1.2 million in Q3 2024. This was driven by higher professional fees related to capital raising and increased R&D expenditures for clinical programs. For the nine months ended September 30, 2025, expenses were $8.6 million compared to $6.3 million in the prior year.
• Net Loss: Net loss widened to $3.1 million in Q3 2025 from $1.1 million in Q3 2024. The nine-month loss increased to $8.7 million from $6.0 million.
• Liquidity: Cash and cash equivalents decreased from $2.3 million at year-end 2024 to $1.7 million at September 30, 2025. Net cash used in operating activities was $5.6 million for the nine months ended September 30, 2025.
• Capital Structure: The company issued $0.9 million in convertible notes in May 2025 and raised approximately $4.4 million in net proceeds from equity offerings (common stock and warrants) during the nine-month period. A 1-for-6 reverse stock split was effective in June 2025.
• Digital Assets: The company adopted ASU 2023-08 and purchased Solana (SOL) tokens with a cost basis of $250,000, recorded at a fair value of $325,000 as of September 30, 2025.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. The company requires additional funding to continue operations and has no assurance of success in raising capital.
• Clinical Progress:
  • ART27.13: Interim results from the Phase 2a CAReS trial showed compelling weight gain (6.38% increase) in treated patients compared to placebo (-5.42% loss). Safety profile remains favorable.
  • ART26.12: Completed Phase 1 Single Ascending Dose study in healthy volunteers with no drug-related adverse events observed.
• Financing Activities:
  • On October 1, 2025 (subsequent event), the company closed an underwritten offering for gross proceeds of approximately $2.0 million.
  • On October 28, 2025 (subsequent event), the company issued new convertible notes ($0.69 million principal) and warrants by converting existing notes.
  • A planned $9.5 million PIPE transaction in August 2025 was terminated.
• Risks: Key risks include the inability to raise additional capital, volatility in digital asset valuations (SOL), dependence on clinical trial outcomes, and potential dilution from future equity issuances.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.7 million cash balance against the $8.7 million nine-month burn rate and upcoming clinical trial costs.
• Debt Obligations: Review the terms of the $0.9 million convertible notes (12% interest, 180-day maturity) and the subsequent October 2025 refinancing to assess immediate liquidity pressure.
• Digital Asset Exposure: Confirm the valuation methodology and risk management protocols for the $325,000 Solana (SOL) holding, which impacts net income volatility.
• Clinical Milestones: Monitor enrollment and data readouts for the ART27.13 Phase 2a trial and ART26.12 Phase 1b/2a progression.
• Dilution Impact: Assess the impact of recent and planned equity offerings (including the October 2025 offering) on existing shareholder ownership.